Skip to main content
Bio Solution Co.,Ltd. logo

Bio Solution Co.,Ltd. — Investor Relations & Filings

Ticker · 086820 ISIN · KR7086820008 KO Manufacturing
Open in API
Filings indexed 215 across all filing types
Latest filing 2026-02-12 Management Reports
Country KR South Korea
Listing KO 086820

About Bio Solution Co.,Ltd.

https://bio-solution.co.kr/

Bio Solution Co., Ltd. is a biotechnology company focused on the development, manufacturing, and sale of cell therapy products. The company's core activities involve cell-based biotechnology, producing therapeutics such as autologous chondrocyte treatments for cartilage regeneration. In addition to its therapeutic offerings, Bio Solution develops human tissue models and provides alternative testing solutions. The company also manufactures and distributes a portfolio of bio-laboratory products, including ready-to-use kits, staining solutions, and various reagents for molecular biology research and development applications.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Biosolution) announcing a significant change (over 30%) in revenue or profit structure compared to the previous fiscal year. This is a standard regulatory disclosure requirement in the Korean market (often referred to as a 'Fair Disclosure' or 'Significant Change' filing). Since it provides key financial highlights and performance metrics for the fiscal year but is not the full audited annual report, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial results.
2026-02-12 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (펠렛형 동종 연골세포치료제(카티로이드)의 호주 제1/2상 임상시험계획 승인)
Legal Proceedings Report Classification · 95% confidence The document is a formal regulatory filing from a Korean company (BioSolution) submitted to the Korea Exchange (KRX). It details a 'Major Management Matter' regarding the approval of a clinical trial (Phase 1/2 for Cartiroid). Since this is a specific regulatory disclosure of a material event (clinical trial approval) rather than a financial report, audit, or presentation, it falls under the 'Regulatory Filings' category.
2026-01-14 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (the 26th Annual General Meeting). It is a standard corporate notice informing shareholders of the record date for voting rights. Since it is a regulatory announcement regarding a meeting process rather than the meeting materials themselves or a financial report, it falls under the general regulatory filing category.
2025-12-16 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (동종 연골세포 스페로이드(스페로큐어)의 제1/2a상 임상시험계획 승인신청)
Regulatory Filings Classification · 95% confidence The document is a disclosure about a clinical trial plan approval application related to a pharmaceutical product. It includes detailed information about the clinical trial phase, purpose, methodology, and regulatory submission date. The document is short (1966 characters) and focuses on an investment judgment related to a clinical trial plan approval. It does not contain financial statements, earnings data, or management discussion of financial results. It is a regulatory announcement about a significant business event (clinical trial plan submission) that could impact investment decisions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-10 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (펠렛형 동종 연골세포치료제(카티로이드)의 호주 제1/2상 임상시험계획 승인신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (BioSolution) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for approval of a Phase 1/2 clinical trial for a cartilage cell therapy product in Australia. Since this is a formal regulatory disclosure of a material event (clinical trial application) that does not fit into specific categories like financial reports, M&A, or dividends, it falls under the general regulatory filing category.
2025-09-17 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, purpose, and the fact that IR materials will be posted on the Korea Exchange (KIND) system. Since this is a short announcement notifying the public of an event and the future availability of materials, rather than the presentation itself, it falls under the category of a regulatory announcement regarding report/event publication.
2025-08-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.